Eli Lilly said its experimental daily obesity pill helped patients maintain most of their weight loss after switching from injectable drugs like Zepbound. MAGA reacts to new video from deadly ...

Fifteen years after Animal and Cannibal, Kesha is finally feeling glittery again. Now that her long legal battle with producer Dr. Luke is over, she’s ready to reembrace her career breakthrough, which ...

All the Latest Game Footage and Images from Magical Princess Lily Go on a journey with Ritsu and Lily to uncover the secrets behind the Kuzono Group, a shady pharmaceutical corporation with nefarious ...

Eli Lilly has pulled out of the central nervous system (CNS)-focused portion of a $960 million biobucks deal centered on Rigel Pharmaceuticals’ receptor-interacting serine/threonine-protein kinase 1 ...

In an effort to “address the implications” of artificial intelligence, the Lilly Endowment is launching a $500 million initiative to provide funding to Indiana colleges and universities to support the ...

Lilly Endowment Inc. is launching a new initiative to help Indiana colleges and universities address artificial intelligence. The endowment is allocating up to $500 million in funding for the ...

CNBC’s Angelica Peebles and Eli Lilly chairman and CEO David Ricks join 'Squawk Box' to discuss the company's quarterly earnings results, late-stage trial data on its experimental obesity pill ...

A glitch in New York’s Summer Youth Employment Program (SYEP) cards allowed massive ATM withdrawals totaling $17 million in just three days. Some teens reportedly sold their cards for $1,000 each, as ...

There might be a way for average American families to set their children up to retire with millions in the bank, even if they don’t go to college. That’s according to a video posted on social media in ...

The phrase “doctor’s orders” does not hold much weight with Generation Z. A new global survey from communications firm Edelman found about 45% of respondents ignore advice from trained medical ...

Eli Lilly (NYSE:LLY) announced it would appeal a decision by the U.K. health authorities not to recommend the company’s new Alzheimer’s therapy, Kisunla, for use within the country’s state-run ...